Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 158673
Licensor has rights relating to a pharmaceutical product known as Ethyol(R) (amifostine) which is being developed by Licensor for use in reducing toxicities of chemotherapeutic cancer treatments and as a radioprotective agent and Licensor has rights relating to a pharmaceutical product known as NeuTrexin(R) (trimetrexate glucuronate for injection).
Amifostine is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.
IPSCIO Record ID: 158672
The Trademark means the trademark Ethyol(R) or the trademark NeuTrexin(R).
IPSCIO Record ID: 262736
IPSCIO Record ID: 163538
License of the Compounds.
(a) From the date of this Letter Agreement until the completion of the IPO or an Alternative Financing, Licensee may request Universitys written consent for Licensee to use one or more of the Compounds to conduct clinical studies. Licensee will also have the right to describe, and to provide information regarding, the Compounds to facilitate the completion of the IPO or an Alternative Financing.
(b) Upon the completion of the IPO or an Alternative Financing, Licensor B will grant or assign to Licensee, and University will take any action necessary to consent to the grant or assignment by Licensor B to Licensee of, an exclusive worldwide license to use, manufacture, have manufactured, promote, sell, distribute or otherwise dispose of any and all products based directly or indirectly on the Current Compounds (the Current Products).
(c) Licensee will have the right to grant sublicenses to any third party who agrees to be bound by the terms of this Letter Agreement in accordance with the terms of its License Agreement with University.
(d) Upon completion of the IPO or an Alternative Financing, University will grant to Licensee, and Licensor B will take any action necessary to consent to the grant by University to Licensee of, an exclusive worldwide license to use, manufacture, have manufactured, promote, sell, distribute or otherwise dispose of any and all products based directly or indirectly on the Future Compounds (the Future Products and, collectively with the Current Products, the Products).
Invention Filed In Issued-App. or Patent #
Dications – Treatment of Pneumocystis carinii US US – June 12, 1990 4,933,347
Dications – Treatment of Leishmaniasis US US – April 13, 1993 5,202,320
ions – Treatment of Malaria US, EPO, Argentina, US – April 27, 1993 5,206,236
(0RS88-4) Brazil, Australia, Canada EPO – March 1, 1995 0,366,066
China, Denmark, Israel, Argentina – May 31, 1995 248,011
Japan, Mexico, Pakistan, Australia – Jan 25, 1993 626,033
Philippines, Korea, Mexico – August 30, 1995 179,371
Switzerland, Venezuela, Pakistan – Oct. 19, 1989 131,965
Finland, India, Norway, Switzerland – Apr 30, 1996
Taiwan Venezuela – Jan 5, 1996
Dications – Treatment of Fungal Infections US DIV-08/641,510
HIV – Inhibition of the Integrase Enzyme US, PCT, Australia, Brazil, US- 08,185,079 NZ-279619
(0RS94-34) Canada, Japan, New PCT- PCT/US95/01599
Zealand, EPO, Venezuela AU- 16798/95 VZ-503-96
Dications – Detection of nucleic acids and US, PCT
cytoskeleton elements (0RS94-43)
Inhibition of Pneumocystis carinii Pneumonia US, PCT, Argentina, Israel, US – May 28, 1996 5,521,189
(0RS94-81) South Africa, Taiwan DIV-08/564,879
Inhibition of Giardia Lamblia US, PCT, Argentina, Israel,
(0RS94-81) South Africa, Taiwan
Inhibition of Cryptosporidium parvum US, PCT, Argentina, Israel,
(0RS94-81) South Africa, Taiwan
Inhibition of Pneumocystis carinii Pneumonia US, Canada, PCT, Japan, US – June 27, 1995 5,428,051
(0RS93-17) Brazil, Australia, New
Zealand, EPO, Venezuela
Prodrugs for PCP Infection US USSN-08/558,716
Methods of Treating Microbial Infections US USSN-08/474,440
The Licensee has two dicationic compounds ready to begin human clinical trials. The first compound, DAP-092, is for the treatment of Cryptosporidium parvum, a parasite that causes severe diarrhea and wasting. The second compound, DB-289, is for the treatment of Pneumocystis carinii pneumonia. These two orally administered drugs are ideally suited to demonstrate the power of the dicationic technology platform. DAP-092 was developed to treat a parasite that is found only in the gastro-intestinal tract ('gut'). DAP-092, because of its positive charges, cannot cross the digestive membranes, and stays in the digestive tract.